<DOC>
	<DOCNO>NCT02319642</DOCNO>
	<brief_summary>This study continue evaluate safety &amp; efficacy Certolizumab Pegol ( CZP ) 6 month Chinese subject active Rheumatoid Arthritis participate RA0044 .</brief_summary>
	<brief_title>An Open-label Extension Study Certolizumab Pegol Chinese Patients With Rheumatoid Arthritis Who Enrolled RA0044</brief_title>
	<detailed_description>This study ( RA0078 ) continue assess safety , tolerability , efficacy Certolizumab Pegol ( CZP ) 6 month additional medication methotrexate ( MTX ) without folic acid Chinese subject active Rheumatoid Arthritis ( RA ) participate main feeder study , RA0044 . All subject continue receive establish treatment MTX without folic acid . The dose MTX may decrease Investigator due toxicity , discontinue completely . Concomitant nonsteroidal anti-inflammatory drug oral corticosteroid permit . For subject , study duration last maximum approximately 32 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>An Institutional Review Board ( IRB ) / Independent Ethics Committee ( IEC ) approve write Informed Consent form ( ICF ) RA0078 sign date subject parent ( ) legal representative Subject/ legal representative consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule , medication intake accord judgment Investigator Subjects must either : Completed RA0044 Week 24 , OR Failed achieve ACR20 response Week 12 ( confirm Week 14 ) RA0044 Subjects must comply protocol requirement participation RA0044 Subjects enter RA0078 complete RA0044 must clear chest xray Week 24 Completion Visit RA0044 . Subjects enter RA0078 Week 16 RA0044 study require chest xray prior enrollment Subject able continue treatment Methotrexate ( MTX ) ( without folic acid ) dose deem appropriate Investigator Female subject childbearing potential negative pregnancy test Entry medically accept method contraception use entire duration study 10 week last dose Certolizumab pegol ( CZP ) . Medically accept method contraception : hormonal contraception least 2 cycle prior Screening , intrauterine device , implant device , diaphragm spermicide , bilateral tubal ligation , monogamous relationship vasectomize ( least 3 month prior Screening ) partner , use condom spermicide gel . Abstinence acceptable method contraception study . Female subject postmenopause least 2 year undergone complete hysterectomy , bilateral tubal ligation and/ bilateral ovariectomy , congenital sterility consider childbearing potential . Male subject must agree ensure use adequate contraception study least 10 week subject receives last dose study medication Rheumatoid Arthritis ( RA ) diseaserelated exclusion : Subjects diagnosis inflammatory arthritis eg , psoriatic arthritis ankylose spondylitis Subjects secondary , noninflammatory type arthritis ( eg , osteoarthritis fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect CZP subject 's primary diagnosis RA Subjects history infect joint prosthesis time prosthesis still situ Concomitant medication exclusion Subjects must free follow concomitant medication : Any biological therapy RA Any experimental therapy , within outside clinical trial ( except RA0044 ) Live vaccine Medical history exclusion Lactating and/or pregnant female subject Male subject childbearing potential partner ( ) female subject childbearing potential NOT practice effective birth control . All female subject must test negative urine pregnancy test study entry study visit Subjects know TB infection , high risk acquire TB infection , latent TB ( LTB ) infection ( exception ) exclude Subjects 3 infection require systemic antibiotic RA0044 Subjects history chronic infection , recent serious lifethreatening infection ( within 6 month , include herpes zoster ) , current sign symptom may indicate infection ( eg , fever , cough ) Subjects history active systemic/ respiratory infection due fungal , parasitic , mycotic pathogen include limited histoplasmosis , coccidiosis , paracoccidiosis , pneumocystis , blastomyces , aspergillus , nontuberculous mycobacteria ( NTMB ) Radiographic evidence suggestive infection sufficient ground exclusion Subjects high risk infection Investigator 's opinion ( eg , subject leg ulcer , indwell urinary catheter , persistent recurrent chest infection , subject permanently bedridden wheelchair bound ) Subjects know positive hepatitis B surface antigen ( HBsAg ) test and/ hepatitis C virus antibody ( antiHCV ) test result Subjects know human immunodeficiency virus ( HIV ) infection Subjects lymphoproliferative disorder include lymphoma sign symptom suggestive lymphoproliferative disease time Subjects active malignancy type Subjects history blood dyscrasia , eg , leukemia hemophilia blood constituent abnormal present abnormal quantity . Subjects class III IV congestive heart failure New York Heart Association ( NYHA ) 1994 Subjects suspect diagnosed demyelinating disease central nervous system ( eg , multiple sclerosis optic neuritis ) Subjects current recent history , determine Investigator , severe , progressive , and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral disease would interfere subject 's participation study . Abnormal laboratory parameter require exclusion subject detail protocol Subjects adverse reaction Percutaneous Endoscopic Gastrostomy ( PEG ) protein medicinal product know hypersensitivity component study medication comparative drug state protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>TNFÎ± antagonist</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Chinese patient</keyword>
	<keyword>Open-label</keyword>
</DOC>